上市首日，三元生物创下上市以来最高价报146.00元。该股目前处于破发状态。 三元生物首次公开发行股票募集资金总额为36.86亿元，扣除发行费用后募集资金净额为35.47亿元。该 公司最终募集资金净额比原计划多26.47亿元。三元生物于2022年1月28日披露的招股说明书显示，该公 司拟募集资金9.00亿元，分别用于年产50000吨赤藓糖醇及技术中心项目、研发信息中心建设项目、补 充流动资金。 中国经济网北京5月28日讯三元生物（301206）(301206.SZ)今日股价下跌，截至收盘报29.60元，跌幅 3.58%。 三元生物于2022年2月10日在深交所创业板上市，公开发行3372.10万股，发行价格为109.30元/股，保荐 机构(主承销商)为中信建投（601066）证券股份有限公司，保荐代表人为陆丹君、陈磊。 2022年6月10日，三元生物披露了2021年年度权益分派实施公告。公司2021年年度权益分派方案为：以 公司现有总股本1.35亿股为基数，向全体股东每10股派10元现金(含税)，同时，以资本公积金向全体股 东每10股转增5股。分红前公司总股本为1.35亿股，分红后总股本增至2.02亿股。本次 ...

证券代码：301206 证券简称：三元生物 公告编号：2025-051 山东三元生物科技股份有限公司 2024 年年度股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会未出现否决议案的情形。 2、本次股东大会未涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 （一）会议召开情况 1、会议召开时间： 现场会议时间：2025 年 5 月 26 日（星期一）15:00 网络投票时间：通过深圳证券交易所交易系统进行网络投票的具体时间为： 2025 年 5 月 26 日 9:15—9:25，9:30—11:30 和 13:00—15:00；通过深圳证券交易 所互联网投票系统的具体时间为：2025 年 5 月 26 日 9:15 至 15:00 2、会议召开地点：山东省滨州市滨北梧桐十路 101 号三元生物公司会议室 3、会议召开方式：现场表决和网络表决相结合的方式 4、会议召集人：董事会 5、会议主持人：董事长聂在建 6、召开情况合法、合规、合章程性说明：本次会议的召集、召开与表决程 序符合《公司法》《深圳证券交易所 ...

北京市东城区建国门内大街 26 号新闻大厦 7 层、8 层 电话：010-88004488/66090088 传真：010-66090016 邮编：100005 北京国枫律师事务所 关于山东三元生物科技股份有限公司 2024 年年度股东大会的 致：山东三元生物科技股份有限公司（贵公司） 北京国枫律师事务所（以下简称"本所"）接受贵公司的委托，指派律师出席并见证 贵公司 2024 年年度股东大会（以下简称"本次会议"）。 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民 共和国证券法》（以下简称"《证券法》"）、《上市公司股东会规则》（以下简称"《股 东会规则》"）、《律师事务所从事证券法律业务管理办法》（以下简称"《证券法律业务管 理办法》"）、《律师事务所证券法律业务执业规则（试行）》（以下简称"《证券法律业务 执业规则》"）等相关法律、行政法规、规章、规范性文件及《山东三元生物科技股份有 限公司章程》（以下简称"《公司章程》"）的规定，就本次会议的召集与召开程序、召集 人资格、出席会议人员资格、会议表决程序及表决结果等事宜，出具本法律意见书。 对本法律意见书的出具，本所律师特作如 ...

Core Viewpoint - Binzhou City is committed to implementing the "industrial city, manufacturing strong city" strategy, focusing on transforming traditional industries, promoting emerging industries, and developing a modern industrial system with strong support [1][16]. Group 1: Industrial Development - Binzhou has cultivated five trillion-level pillar industries, four strategic emerging industries, and three future industries, establishing a matrix of industrial development [1][16]. - The city has built two provincial advanced manufacturing clusters and seven provincial characteristic industrial clusters, maintaining its position as one of the top 100 advanced manufacturing cities in the country for four consecutive years [1][16]. - In 2024, the revenue for high-end aluminum, fine chemicals, and intelligent textile industry clusters is projected to reach 471.1 billion yuan, 241.3 billion yuan, and 192 billion yuan respectively, showcasing the strong momentum of industrial transformation [1][16]. Group 2: Economic Performance - Binzhou's GDP is expected to exceed 340 billion yuan in 2024, achieving a year-on-year growth of 6.2%, which is higher than the national average [4]. - The industrial output value above designated size is projected to grow by 9.6% year-on-year, with manufacturing growth at 11.8%, particularly in equipment manufacturing, which is expected to grow by 16.1% [6]. - High-tech manufacturing value added is expected to grow by 22.3%, significantly outpacing the average growth rate of industrial enterprises [6]. Group 3: Innovation and Technology - The number of national high-tech enterprises in Binzhou has surpassed 800, with a year-on-year growth of 21.3%, maintaining over 20% growth for three consecutive years [8]. - The city has approved 66 provincial-level technology projects, receiving 220 million yuan in financial support, marking a historical high [8]. - The establishment of the "Binzhou Aluminum Industry Advanced Manufacturing Provincial Laboratory" represents a significant breakthrough in innovation platform construction [8]. Group 4: Policy Framework - The "New Quality Productive Forces" concept has been incorporated into the national strategy, with Binzhou actively responding by implementing policies to foster innovation and industrial development [10][11]. - A series of forward-looking policies have been introduced to support the development of advanced manufacturing clusters and new generation information technology industries [11][14]. - The government aims to create a manufacturing strong city with core competitiveness by focusing on high-end, intelligent, green, and clustered industrial development [11][16]. Group 5: Future Trends - Binzhou is expected to strengthen traditional industry upgrades, particularly in high-end aluminum, and expand into new areas such as renewable energy and low-altitude economy [27][30]. - The integration of digital technology and intelligent manufacturing is anticipated to enhance industrial transformation, with plans to cultivate over 500 benchmark enterprises [29]. - The city aims to optimize its innovation ecosystem, enhancing collaboration between government, industry, academia, and research to boost technology transfer and innovation [31].

Group 1 - The sugar substitute concept is experiencing a decline in the afternoon trading session, with Baolingbao (002286) nearing a trading halt [1] - Other companies in the sector, including Sanyuan Bio (301206), Jinhai Bio (002688), Vinegar Chemical (603968), and Xinghuo Technology (600866), are also seeing a drop in stock prices [1] - There is an influx of dark pool funds entering these stocks, indicating potential interest from institutional investors [1]

日前，美国商务部公布了对原产于中国的赤藓糖醇产品反倾销和反补贴调查结果，三元生物（301206.SZ）适用3.49%的反补贴税，中国其他生产商/出口商 的税率为3.47%。 2024年，三元生物营收为7.13亿元，同比增长42.72%；净利润为1.05亿元，同比增长87.47%。其中，国外市场营收为4.94亿元，同比增长33.18%，占总营收 比重约为70%。 2025年第一季度，三元生物营收为1.50亿元，同比下滑21.73%；净利润为2491.40万元，同比增长2.75%，增速较2024年有明显回落。 对此，三元生物发布公告称，本次美国的反倾销和反补贴调查对其在美市场的销售确实造成了一定影响，后续影响程度仍需结合调查进展及市场变化综合研 判。 三元生物表示，正在采取多种措施积极应对，包括调整销售策略，"内外并重，适度内倾"，重点发力国内健康消费品市场；同时加快推进东南亚、印度、中 东及"一带一路"沿线新兴市场布局，以分散美国市场所带来的不利影响。 值得注意的是，目前反补贴调查尚未结束，上述调查结果为初裁，美国商务部尚需进一步核查后作出最终裁定，预计2025年9月24日将发布最终裁决结果。 公开资料显示，三 ...

Group 1: Company Performance and Market Conditions - The company is currently preparing for the launch of a glucose syrup production project with an annual capacity of 80,000 tons, which is still in the preparatory stage [6] - The company reported a significant impact from the EU's anti-dumping tariffs, with a 156.7% increase in tariffs affecting sales [3] - The company is actively seeking to diversify its market presence, particularly in Southeast Asia, South Korea, and Japan, to reduce reliance on the EU and US markets [8] Group 2: Product Development and Market Strategy - The company is focusing on the development of alternative sweeteners, such as allulose and tagatose, to meet the growing demand for healthier options [9] - The production capacity for allulose is currently 10,000 tons, with plans for an additional 10,000 tons under construction [19] - The company aims to capture a potential market of 770,000 tons per year by replacing just 1% of the global sugar consumption of 77 million tons [23] Group 3: Financial and Investment Strategies - The company has a high per-share reserve of 17.3859 yuan and is considering stock conversion options to enhance liquidity [8] - The company is exploring acquisition opportunities to strengthen its position in the synthetic biology sector and enhance its competitive edge [11] - The company is committed to maintaining its current production capacity for erythritol despite ongoing technological upgrades [20] Group 4: Regulatory and Compliance Issues - The company is closely monitoring the US anti-dumping investigation, with initial rulings expected by July 11, 2025 [4] - The company is adjusting its production processes in response to EU anti-dumping regulations and is working with legal experts to navigate these challenges [9] - The company is actively engaging with US clients to capitalize on recent tariff adjustments, aiming to secure more orders [18]

Group 1 - Vanke A received a loan of 1.552 billion yuan from its largest shareholder, Shenzhen Metro Group, to repay the principal and interest of publicly issued bonds, with a loan term of 36 months and an annual interest rate of 2.34%, lower than the 1-year LPR [2] - Chengfei Integration announced that its stock has been on a six-day trading limit, confirming that there are no undisclosed significant matters affecting the company [3] - Dongpeng Beverage's shareholder, Kunpeng Investment, reduced its shareholding from 6.44% to 5.43%, a decrease of 1.01 percentage points, through trading activities [4] Group 2 - Baofeng Energy plans to repurchase shares worth between 1 billion and 2 billion yuan, with a maximum repurchase price of 22.80 yuan per share [7] - Huakayi Yibai announced that shareholders plan to reduce their holdings by up to 3% of the company's total shares [6] - China Pacific Insurance reported a 10.4% year-on-year increase in original insurance premium income for its life insurance subsidiary, totaling 115.359 billion yuan [22]

Core Viewpoint - The U.S. Department of Commerce has made a preliminary ruling on countervailing duties for erythritol imported from China, impacting companies like Baolingbao and Sanyuan Biotech, which are adjusting their strategies in response to the investigation [1][2]. Company Responses - Sanyuan Biotech has acknowledged the impact of the U.S. investigation on its sales and is shifting its sales strategy to focus more on the domestic health consumer market while also exploring new markets in Southeast Asia, India, and the Middle East [1][3]. - Baolingbao, facing a lower anti-dumping tax rate of 34.4% from the EU, has seen a significant increase in revenue from erythritol products in Europe, with a 123% year-on-year growth in Q1 2025 [3]. Industry Challenges - The sugar substitute industry is facing multiple international trade challenges, including anti-dumping investigations from both the U.S. and the EU, with the EU imposing anti-dumping duties ranging from 34.4% to 233.3% [2][3]. - The domestic erythritol market is currently experiencing low prices, but the competitive landscape is easing, which may lead to a more stable supply-demand balance in the future [4]. Financial Performance - In 2024, Sanyuan Biotech reported revenues of 710 million yuan, a 42.7% increase year-on-year, and a net profit of 110 million yuan, up 87.5% [3]. - Baolingbao's revenue for the same period was 2.4 billion yuan, a decrease of 4.8%, but its net profit increased by 106% to 110 million yuan [3].

Group 1 - Vanke A's largest shareholder, Shenzhen Metro Group, plans to provide a loan of up to 1.55 billion yuan to repay the company's bonds [1] - Yidelong reported a net profit of 41.77 million yuan for Q1 2025, a year-on-year increase of 34.19% [1] - Overseas Chinese Town A achieved a contract sales amount of 1.78 billion yuan in April, a year-on-year increase of 10% [1][2] Group 2 - Dajin Heavy Industry's subsidiary signed a contract worth approximately 1 billion yuan for an offshore wind power project with a European energy company [4] - Liao Port Co. announced the resignation of Chairman Wang Zhixian due to reaching retirement age [4] - China Energy Construction's application for a specific stock issuance has been approved by the Shanghai Stock Exchange [6] Group 3 - Xinhua Insurance reported a 27% year-on-year increase in premium income from January to April, totaling 85.38 billion yuan [11] - 吉祥航空's passenger turnover increased by 6.34% in April, with a seat occupancy rate of 86.16% [13] - New City Holdings reported a contract sales amount of approximately 1.76 billion yuan in April, a year-on-year decrease of 52.46% [28] Group 4 - Three Yuan Bio announced a preliminary ruling of a 3.49% countervailing duty on its products in the U.S. [23] - Shanghai Pharmaceutical's product, Wengjing Decoction Granules, has been approved for production [20] - A strategic cooperation agreement was signed between *ST Dali and Zhuhai Yunzhou Intelligent Technology Co., Ltd. to promote the development of intelligent unmanned equipment [22] Group 5 - The construction of the automotive lightweight forging precision processing project by Sanlian Forging has been completed [25] - The company Tianma Technology reported an output of approximately 1,480.16 tons of eel in April [18][19] - The company Victory Technology plans to invest up to 3 billion yuan for share repurchase [42]